Cresco Labs (CL) Resumen de Acciones
Cresco Labs Inc. cultiva, fabrica y vende al por menor productos de cannabis medicinal en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 6/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Cresco Labs Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | CA$1.15 |
| Máximo en las últimas 52 semanas | CA$3.12 |
| Mínimo de 52 semanas | CA$0.60 |
| Beta | 1.71 |
| Cambio en 1 mes | 2.68% |
| Variación en 3 meses | -11.54% |
| Cambio de 1 año | 71.64% |
| Variación en 3 años | -48.20% |
| Variación en 5 años | -91.09% |
| Variación desde la OPV | -82.44% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 04
CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile
Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.Actualización de narrativa • May 05
CL: Lower P/E Expectations Will Support A More Upside Skewed Profile
Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.Recent updates
Actualización de narrativa • Jun 04
CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile
Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.Actualización de narrativa • May 05
CL: Lower P/E Expectations Will Support A More Upside Skewed Profile
Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.
Actualización de narrativa • Apr 20
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.Actualización de narrativa • Apr 05
CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.Actualización de narrativa • Mar 22
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Actualización de narrativa • Mar 07
CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.Actualización de narrativa • Feb 21
CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Artículo de análisis • Feb 12
Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...Actualización de narrativa • Feb 06
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).Actualización de narrativa • Jan 23
CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.Actualización de narrativa • Jan 09
CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).Actualización de narrativa • Dec 15
CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Artículo de análisis • Nov 26
Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...Artículo de análisis • Nov 08
Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Oct 12
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...Artículo de análisis • Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Jul 31
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Artículo de análisis • Jul 23
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Jun 15
Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...Artículo de análisis • May 01
Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
Nueva narrativa • Mar 29
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Artículo de análisis • Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...Artículo de análisis • Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Artículo de análisis • Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...Artículo de análisis • Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...Artículo de análisis • Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...Artículo de análisis • Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...Artículo de análisis • Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...Artículo de análisis • Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...Artículo de análisis • Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)
There wouldn't be many who think Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.7x is worth a...Rentabilidad de los accionistas
| CL | CA Pharmaceuticals | Mercado CA | |
|---|---|---|---|
| 7D | -7.3% | -5.2% | 1.5% |
| 1Y | 71.6% | 56.9% | 31.8% |
Rentabilidad vs. Industria: CL superó a la industria Canadian Pharmaceuticals, que obtuvo un rendimiento del 56.9% el año pasado.
Rentabilidad vs. Mercado: CL superó al mercado Canadian, que obtuvo un rendimiento del 31.8% el año pasado.
Volatilidad de los precios
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 16.8% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 10.1% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 3.7% |
Precio estable de las acciones: El precio de las acciones de CL ha sido volátil durante los últimos 3 meses en comparación con el mercado Canadian.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CL ha disminuido de 22% a 17% en el último año, pero sigue siendo superior al 75% de los valores de Canadian.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| n/a | 2,900 | Charlie Bachtell | www.crescolabs.com |
Cresco Labs Inc. cultiva, fabrica y vende al por menor productos de cannabis medicinal en Estados Unidos. Ofrece cannabis en flores, vaporizadores, resinas vivas, bolígrafos desechables y extractos bajo la marca Cresco; carros de vaporización, vaporizadores, flores, palomitas de maíz, batidos, pre-rolls, shorties y concentrados bajo la marca High Supply; vaporizadores y gominolas bajo la marca Good News; vaporizadores y comestibles bajo la marca Wonder Wellness Co.; y tinturas, cápsulas, bálsamos y aceites sublinguales bajo la marca Remedi. La empresa ofrece flores de cannabis bajo la marca FloraCal; y aceites de cannabis y variedad de bocados disponibles en múltiples niveles de potencia bajo la marca Mindy's Edibles, así como licencias de la marca Kiva.
Resumen de fundamentos de Cresco Labs Inc.
| Estadísticas fundamentales de CL | |
|---|---|
| Capitalización bursátil | CA$522.26m |
| Beneficios(TTM) | -CA$187.42m |
| Ingresos (TTM) | CA$896.80m |
0.5x
Ratio precio-ventas (PS)-2.3x
Ratio precio-beneficio (PE)¿Está CL sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CL | |
|---|---|
| Ingresos | US$641.42m |
| Coste de los ingresos | US$320.03m |
| Beneficio bruto | US$321.39m |
| Otros gastos | US$455.43m |
| Beneficios | -US$134.05m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.36 |
| Margen bruto | 50.11% |
| Margen de beneficio neto | -20.90% |
| Ratio deuda/patrimonio | 137.3% |
¿Cómo se ha desempeñado CL a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/14 21:18 |
| Precio de las acciones al final del día | 2026/06/12 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cresco Labs Inc. está cubierta por 13 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |